Legend Star has contributed to a $37.5m round for HifiBio, which is developing antibody treatments for cancer and autoimmune diseases.

HifiBio, a US-based biopharmaceutical company focusing on cancer and autoimmune diseases, has closed an oversubscribed $37.5m series B round featuring Legend Star Capital, an investment vehicle for conglomerate Legend Holdings.

Venture capital firm Sequoia China and life sciences investment firm Lyfe Capital co-led the round, which also included VI Ventures, Nest.Bio Ventures and Proxima Ventures.

HifiBio is working on therapeutic antibodies that will use the body’s own immune system to tackle cancer and autoimmune diseases. It is also pursuing open…